Filing Flows › Tactile Systems Technology (TCMD) › Q2 2026 › vs Q2 2025
Tactile Systems Technology (TCMD) Q2 2026 vs Q2 2025 (year over year)
Tactile Systems Technology's revenue rose $6.8M (+9%) from $78.9M in Q2 2025 to $85.7M in Q2 2026. The biggest changes: Lymphedema products +$7.7M (+12%); Airway clearance products −$868K (-7%). Gross margin 76.3% against 74.5% (+1.7 pts).
Tactile Systems Technology, Q2 2026: revenue $85.7M (+9% year over year), operating margin 8.0%, net earnings $7.8M, operating cash flow $3.3M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Gross margin | 76.3% | 74.5% | +1.7 pts |
| Operating margin | 8.0% | 5.2% | +2.8 pts |
| Net margin | 9.1% | 4.1% | +5.0 pts |
| Free cash flow margin | 2.3% | 18.2% | -15.9 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Lymphedema products | $73.6M | $66.0M | $7.7M | +12% |
| Airway clearance products | $12.1M | $12.9M | −$868K | -7% |
| Revenue | $85.7M | $78.9M | $6.8M | +9% |
| Gross profit | $65.3M | $58.8M | $6.6M | +11% |
| Cost of revenue | $20.3M | $20.1M | $237K | +1% |
| Other income, net | $542K | $441K | $101K | +23% |
| Operating profit | $6.8M | $4.1M | $2.7M | +67% |
| Operating expenses | $58.5M | $54.7M | $3.8M | +7% |
| Pre-tax earnings | $7.4M | $4.5M | $2.8M | +63% |
| Research & development | $2.5M | $2.0M | $483K | +24% |
| Sales & marketing | $32.0M | $30.0M | $2.0M | +7% |
| General & admin | $23.4M | $22.0M | $1.3M | +6% |
| Other operating costs | $650K | $619K | $31K | +5% |
| Income tax benefit | $417K | −$1.3M | $1.7M | — |
| Net earnings | $7.8M | $3.2M | $4.6M | +142% |
| Operating cash sources | $11.9M | $6.8M | $5.0M | +74% |
| Depreciation & amortization | $1.8M | $1.7M | $152K | +9% |
| Share-based compensation | $2.3M | $1.9M | $321K | +17% |
| Working capital & other | $8.6M | −$7.9M | $16.5M | — |
| Operating cash flow | $3.3M | $14.8M | −$11.5M | -78% |
| Free cash flow (OCF − capex) | $2.0M | $14.4M | −$12.4M | -86% |
| Capital expenditures | $1.3M | $369K | $912K | +247% |
Questions
How much did Tactile Systems Technology's revenue grow year over year in Q2 2026?
Tactile Systems Technology's revenue rose $6.8M (+9%) from $78.9M in Q2 2025 to $85.7M in Q2 2026.
What drove Tactile Systems Technology's revenue change in Q2 2026?
Lymphedema products +$7.7M (+12%); Airway clearance products −$868K (-7%).